Karyopharm Therapeutics, Inc - Recruiting 18 years or older. - A Phase II, Two-tier Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients With Recurrent Glioblastoma After Failure of Radiation Therapy and Temozolomide.
Genentech - Recruiting 18 years or older. - An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma.
Bristol-Myers Squibb - Recruiting 18 years or older. - A Randomized Phase IIb, Open Label Study of Nivolumab or Nivolumab in Combination With Ipilimumab Versus Bevacizumab in Adult Subjects With Recurrent Glioblastoma (GBM).
GenSpera, Inc. - Recruiting 18 years or older. - An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy, Safety and CNS Exposure of G-202 in Patients With Recurrent or Progressive Glioblastoma.
Washington University School of Medicine - Recruiting 18 years or older. - A Pilot Study of Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Doxorubicin in the Treatment of Recurrent Glioblastoma Multiforme.
Amgen - Recruiting 18 years or older. - A Phase 1 First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 595 in Subjects With Recurrent Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII).
Cortice Biosciences, Inc. - Recruiting 18 years or older. - Phase 2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab in Adults With Recurrent or Progressive Glioblastoma Following Bevacizumab Alone.
National Cancer Institute (NCI) - Recruiting 18 years or older. - Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma.
GW Pharmaceuticals Ltd. - Recruiting 18 years or older. - A Two Part Study to Assess the Tolerability, Safety and Pharmacodynamics of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma.
Massachusetts General Hospital - Recruiting 18 years or older. - A Study to Evaluate Vascular Normalization in Patients With Recurrent Glioblastoma Treated With Bevacizumab Using [11C]Temozolomide PET and Vascular MRI.
Tocagen Inc. - Recruiting 18 years to 80 years. - A P1 Ascending Dose Trial of the Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered Intravenously Prior to, and Intracranially at the Time of, Subsequent Resection for Recurrent HGG & Followed by Treatment With Extended-Release 5-FC.
National Cancer Institute (NCI) - Recruiting 18 years or older. - Phase I/Comparative Randomized Phase II Trial of TRC105 Plus Bevacizumab Versus Bevacizumab in Bevacizumab-Nave Patients With Recurrent Glioblastoma Multiforme.
anti-endoglin monoclonal antibody TRC105; bevacizumab; laboratory biomarker analysis; pharmacological study
Pediatric Brain Tumor Consortium - Recruiting 16 years to 21 years. - A Phase I Study of Intratumoral/Peritumoral Herpes Simplex Virus-1 Mutant HSV1716 in Patients With Refractory or Recurrent High Grade Gliomas (HGG).
Northwestern University - Recruiting 18 years or older. - A Phase II Study of the Efficacy of Hypofractionated Radiation Therapy With Bevacizumab and Temozolomide Followed by Maintenance Temozolomide and Bevacizumab for Recurrent High-Grade Gliomas.
Grupo Espa¤ol de Investigaci¢n en Neurooncolog¡a - Recruiting 18 years or older. - A Prospective Multicenter, Open Label, Phase II Pilot Clinical Trial to Evaluate Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation.
Actelion - Recruiting 18 years or older. - A Phase 1/1b, Open-label Study in Patients With Recurrent Glioblastoma to Assess the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide.
Phase 1 Dose Escalation; Phase 1b; Ancillary Study
Johann Wolfgang Goethe University Hospitals - Recruiting 18 years or older. - Calorie-restricted, Ketogenic Diet and Transient Fasting vs. Standard Nutrition During Reirradiation for Patients With Recurrent Glioblastoma: the ERGO2 Study.
calorie-restricted ketogenic diet and transient fasting; standard nutrition
Eisai Inc. - Recruiting N/A or older. - An Open-Label, Multicenter Phase 1b/2 Study of E7050 in Combination With E7080 in Subjects With Advanced Solid Tumors (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2).
E7050 plus E7080; E7080 plus E7050; E7050 plus E7080 or E7080 alone plus E7050 add-on therapy; E7050